Apnimed, Inc. has filed for an initial public offering in the United States as it prepares for a potentially decisive regulatory year for AD109, its once-nightly oral treatment for obstructive sleep apnea. The Cambridge, Massachusetts-based pharmaceutical company plans to list on the Nasdaq Global Market under the ticker APMD, although the number of shares, proposed
Find out how Compass Pathways’ COMP360 Phase 3 data could shape regulated psilocybin treatment for depression.
Find out how UroGen Pharma’s UGN-501 could test oncolytic virus therapy for recurrent non-muscle invasive bladder cancer.
Find out how Gain Therapeutics’ GT-02287 could test GCase restoration as a disease-modifying strategy for Parkinson’s disease.
Find out how QT Imaging’s clean FDA inspection could support Breast Acoustic CT scale-up and breast imaging adoption.
Find out how Parabilis Medicines’ IPO surge could reshape investor appetite for Helicon peptides and Wnt-driven oncology drugs.
Find out how Kardigan’s planned Nasdaq IPO could reshape precision cardiovascular drug development and biotech investor sentiment.
Medtech suppliers are under pressure to prove growth quality. Novanta’s Jefferies appearance may sharpen the investor debate.
Healthcare staffing is still under pressure. Knox Lane’s $437m Cross Country Healthcare deal turns that reset into a private equity wager.
Contineum Therapeutics advances PIPE-791 in IPF and chronic pain while extending cash runway into 2029. Find out what comes next.